Sri Lanka has temporarily halted its COVID-19 vaccination programme as there was a delay in securing more AstraZeneca vaccines from the Serum Institute of India, a top health minister has said.
Sri Lanka launched its inoculation programme late January when India gifted 500,000 doses of Oxford-AstraZeneca. Till Thursday 913,219 people out of the island nation's 21 million population had been vaccinated.
Vaccination programme has been halted from Wednesday night due to the need to use the available Oxford-AstraZeneca doses for the second jab of those already vaccinated, primary health care and COVID-19 prevention minister Dr Sudarshani Fernandopulle was quoted as saying by the Daily Mirror newspaper on Friday.
She said the COVID-19 vaccination programme was temporarily suspended as there was a delay in securing more AstraZeneca vaccines, the report added.
The Serum Institute of India (SII) recently suspended exports of the AstraZeneca vaccine.
The WHO has recommended that the second jab must be made available within 12 weeks of the first. The second dose was to be administered from April 19, the report said.
After the free gift, Sri Lanka placed an order for more doses of the Indian vaccine. The Oxford-AstraZeneca vaccine, Covishield, has been developed in collaboration with SII.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
The Serum Institute had curtailed exports in the recent weeks. So, Fernandopulle said that Sri Lanka was not able to gain any assurances on the arrival of the next consignment from India in time.
This week China donated 600,000 doses of Sinopharm vaccines. However neither the local health regulators or the WHO have approved its emergency use. Officials said the Chinese vaccine will be administered on the Chinese workers in the country.
Sri Lanka is also to order 700,000 doses of the Russian Sputnik V vaccine.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)